1
|
Girouard J, Belgorosky D, Hamelin-Morrissette J, Boulanger V, D'Orio E, Ramla D, Perron R, Charpentier L, Van Themsche C, Eiján AM, Bérubé G, Reyes-Moreno C. Molecular therapy with derivatives of amino benzoic acid inhibits tumor growth and metastasis in murine models of bladder cancer through inhibition of TNFα/NFΚB and iNOS/NO pathways. Biochem Pharmacol 2019; 176:113778. [PMID: 31877271 DOI: 10.1016/j.bcp.2019.113778] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2019] [Accepted: 12/18/2019] [Indexed: 12/19/2022]
Abstract
Muscle-invasive bladder cancer (MIBC) is an aggressive form of urothelial bladder carcinoma (UBC) with poorer outcomes compared to the non-muscle invasive form (NMIBC). Higher recurrent rates and rapid progression after relapse in UBC is known to be linked with chronic inflammation. Here, the preclinical murine models of NMIBC (MB49) and MIBC (MB49-I) were used to assess the antitumor effects of DAB-1, an anti-inflammatory aminobenzoic acid derivative we have developed in order to target cancer-related inflammation. A subchronic toxicity study on cancer-free mice shown that DAB-1 treatment did not affect normal mouse development or normal function of vital organs. In mice bearing MB49-I tumors, whole body accumulation of the radioconjugate [131I]DAB-1 was higher than in control mice, the main sites of [131I]DAB-1 accumulation being the liver (34%), the intestines (21%), and the tumors (18%). In vivo molecular therapy of ectopic and orthotopic tumors indicated that treatment with DAB-1 efficiently inhibited tumor growth, metastasis formation, and mortality rate. The antitumor efficacy of DAB-1 was associated with strong decreased tumor cell proliferation and iNOS expression in tumor tissues and deactivation of macrophages from tumor-bearing mice. Mechanistic investigations revealed that DAB-1 efficiently inhibited i) TNFα/NFΚB and IL6/STAT3 signaling pathways activation; ii) TNFα-induced NO production by decreasing NFΚB transcriptional activation and functional iNOS expression; and iii) cellular proliferation with minimal or no effects on cell mortality or apoptosis. In conclusion, this study provides preclinical and biological/mechanistic data highlighting the potential of DAB-1 as a safe and efficient therapeutic agent for the treatment of patients with NMIBC and MIBC.
Collapse
Affiliation(s)
- Julie Girouard
- Laboratoire de Recherche en Oncologie et Immunobiologie (LROI) et Groupe de Recherche en Signalisation Cellulaire (GRSC), Département de biologie médicale, Université du Québec à Trois-Rivières, Trois-Rivières, QC, Canada
| | - Denise Belgorosky
- Laboratoire de Recherche en Oncologie et Immunobiologie (LROI) et Groupe de Recherche en Signalisation Cellulaire (GRSC), Département de biologie médicale, Université du Québec à Trois-Rivières, Trois-Rivières, QC, Canada; Instituto de Oncología Ángel H. Roffo, Área de Investigación, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Jovane Hamelin-Morrissette
- Laboratoire de Recherche en Oncologie et Immunobiologie (LROI) et Groupe de Recherche en Signalisation Cellulaire (GRSC), Département de biologie médicale, Université du Québec à Trois-Rivières, Trois-Rivières, QC, Canada
| | - Valerie Boulanger
- Laboratoire de Recherche en Oncologie et Immunobiologie (LROI) et Groupe de Recherche en Signalisation Cellulaire (GRSC), Département de biologie médicale, Université du Québec à Trois-Rivières, Trois-Rivières, QC, Canada
| | - Ernesto D'Orio
- Instituto de Oncología Ángel H. Roffo, Área de Diagnóstico por Imágenes y Terapia Radiante, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Djamel Ramla
- Laboratoire de Recherche en Histologie et Pathologie (LRHP), Université du Québec à Trois-Rivières, Trois-Rivières, QC, Canada
| | - Robert Perron
- Centre Hospitalier Affilié Universitaire Régional de Trois-Rivières-Service de pathologie, Trois-Rivières, QC, Canada
| | - Lucie Charpentier
- Centre Hospitalier Affilié Universitaire Régional de Trois-Rivières-Service de pathologie, Trois-Rivières, QC, Canada
| | - Céline Van Themsche
- Laboratoire de Recherche en Oncologie et Immunobiologie (LROI) et Groupe de Recherche en Signalisation Cellulaire (GRSC), Département de biologie médicale, Université du Québec à Trois-Rivières, Trois-Rivières, QC, Canada
| | - Ana Maria Eiján
- Instituto de Oncología Ángel H. Roffo, Área de Investigación, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Gervais Bérubé
- Laboratoire de Recherche en Chimie Médicinale (LRCM) et Groupe de Recherche en Signalisation Cellulaire (GRSC), Département de chimie, biochimie et physique, Université du Québec à Trois-Rivières, Trois-Rivières, QC, Canada
| | - Carlos Reyes-Moreno
- Laboratoire de Recherche en Oncologie et Immunobiologie (LROI) et Groupe de Recherche en Signalisation Cellulaire (GRSC), Département de biologie médicale, Université du Québec à Trois-Rivières, Trois-Rivières, QC, Canada.
| |
Collapse
|
3
|
Kashiwagi E, Inoue S, Mizushima T, Chen J, Ide H, Kawahara T, Reis LO, Baras AS, Netto GJ, Miyamoto H. Prostaglandin receptors induce urothelial tumourigenesis as well as bladder cancer progression and cisplatin resistance presumably via modulating PTEN expression. Br J Cancer 2017; 118:213-223. [PMID: 29123257 PMCID: PMC5785746 DOI: 10.1038/bjc.2017.393] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2017] [Revised: 10/04/2017] [Accepted: 10/06/2017] [Indexed: 12/22/2022] Open
Abstract
Background: We investigated the role of prostaglandin receptors (e.g. prostaglandin E2 receptor 2 (EP2), EP4) and the efficacy of celecoxib in urothelial tumourigenesis and cancer progression. Methods: We performed immunohistochemistry in bladder cancer (BC) tissue microarrays, in vitro transformation assay in a normal urothelial SVHUC line, and western blot/reverse transcription–polymerase chain reaction/cell growth assays in BC lines. Results: EP2/EP4 expression was elevated in BCs compared with non-neoplastic urothelial tissues and in BCs from those who were resistant to cisplatin-based neoadjuvant chemotherapy. Strong positivity of EP2/EP4 in non-muscle-invasive tumours or positivity of EP2/EP4 in muscle-invasive tumours strongly correlated with disease progression or disease-specific mortality, respectively. In SVHUC cells, exposure to a chemical carcinogen 3-methylcholanthrene considerably increased and decreased the expression of EP2/EP4 and phosphatase and tensin homologue (PTEN), respectively. Treatment with selective EP2/EP4 antagonist or celecoxib also resulted in prevention in 3-methylcholanthrene-induced neoplastic transformation of SVHUC cells. In BC lines, EP2/EP4 antagonists and celecoxib effectively inhibited cell viability and migration, as well as augmented PTEN expression. Furthermore, these drugs enhanced the cytotoxic activity of cisplatin in BC cells. EP2/EP4 and PTEN were also elevated and reduced, respectively, in cisplatin-resistant BC sublines. Conclusions: EP2/EP4 activation correlates with induction of urothelial cancer initiation and outgrowth, as well as chemoresistance, presumably via downregulating PTEN expression.
Collapse
Affiliation(s)
- Eiji Kashiwagi
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.,James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
| | - Satoshi Inoue
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.,James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.,Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA.,James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY 14642, USA
| | - Taichi Mizushima
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.,James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.,Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA.,James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY 14642, USA
| | - Jinbo Chen
- Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA.,James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY 14642, USA
| | - Hiroki Ide
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.,James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
| | - Takashi Kawahara
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.,James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.,Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
| | - Leonardo O Reis
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.,James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
| | - Alexander S Baras
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.,James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
| | - George J Netto
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.,James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
| | - Hiroshi Miyamoto
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.,James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.,Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA.,James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY 14642, USA.,Department of Urology, University of Rochester Medical Center, Rochester, NY 14642, USA
| |
Collapse
|
4
|
Anti-inflammatory use may not negatively impact oncologic outcomes following intravesical BCG for high-grade non-muscle-invasive bladder cancer. World J Urol 2016; 35:105-111. [PMID: 27194044 DOI: 10.1007/s00345-016-1853-z] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2016] [Accepted: 05/10/2016] [Indexed: 12/11/2022] Open
Abstract
PURPOSE To evaluate whether anti-inflammatory agents affect outcomes in patients receiving intravesical BCG therapy for high-grade (HG) non-muscle-invasive bladder cancer (NMIBC). METHODS We reviewed the records of 203 patients in a prospective database of HG NMIBC from 2006 to 2012 at a single institution. Patients who had muscle-invasive disease (n = 32), low-grade pathology (n = 4), underwent early cystectomy within 3 months (n = 25), had <3 months of follow-up (n = 11), or did not receive an induction course of intravesical BCG (n = 32) were excluded. Clinicopathologic data were tabulated including demographics, comorbidities, pathologic stage and grades, intravesical therapy, and concomitant use of aspirin, NSAIDs, COX inhibitors, and statins. Multivariate Cox regression analysis explored predictive factors for recurrence, progression (stage progression or progression to cystectomy), cancer-specific survival (CSS), and overall survival (OS). RESULTS Ninety-nine patients with HG NMIBC who received at least one induction course of intravesical BCG were identified, with median follow-up of 31.4 months. There were 20 (20.2 %) deaths, including 6 (6.1 %) patients with bladder cancer-related mortality. 13 % patients experienced tumor progression and 27 % underwent cystectomy following failure of intravesical therapy. Anti-inflammatory use included statins (65 %), aspirin (63 %), or non-aspirin NSAIDs/COX inhibitors (26 %). Anti-inflammatory use was not significantly predictive of recurrence, progression, or mortality outcomes on Cox regression. CIS stage was associated with higher progression, while age, BMI, and Charlson score were independent predictors of overall mortality. CONCLUSION Despite speculation of inhibitory effects on BCG immunomodulation there was no evidence that anti-inflammatory agents impacted oncologic outcomes in patients receiving BCG for HG NMIBC.
Collapse
|
5
|
Knapp DW, Ruple-Czerniak A, Ramos-Vara JA, Naughton JF, Fulkerson CM, Honkisz SI. A Nonselective Cyclooxygenase Inhibitor Enhances the Activity of Vinblastine in a Naturally-Occurring Canine Model of Invasive Urothelial Carcinoma. Bladder Cancer 2016; 2:241-250. [PMID: 27376143 PMCID: PMC4927831 DOI: 10.3233/blc-150044] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Background: Chemotherapy is expected to remain an important part of invasive urothelial carcinoma (UC) treatment. Strategies to enhance chemotherapy efficacy are needed. Objective: To determine the chemotherapy-enhancing effects of a nonselective cyclooxygenase (COX) inhibitor on vinblastine in a naturally-occurring canine model of invasive UC. Methods: With IACUC approval, privately-owned dogs with naturally-occurring histologically-diagnosed invasive UC, expected survival ≥6 weeks, and informed owner consent were randomly allocated to receive vinblastine (2.5 mg/m2 intravenously every 2 weeks) plus piroxicam (0.3 mg/kg daily per os) or vinblastine alone (same dose) with the option to receive piroxicam alone when vinblastine failed. Scheduled evaluations included physical exam, standard laboratory analyses, thoracic radiography, abdominal ultrasonography, and standardized measurement of urinary tract tumors. Results: Dogs receiving vinblastine alone (n = 27) and vinblastine-piroxicam (n = 24) were similar in age, sex, breed, tumor stage, and grade. Remission occurred more frequently (P < 0.02) with vinblastine-piroxicam (58.3%) than with vinblastine alone (22.2%). The median progression free interval was 143 days with vinblastine alone and 199 days with the combination. Interestingly, the overall median survival time was significantly longer (P < 0.03) in dogs receiving vinblastine alone followed by piroxicam alone (n = 20, 531 days) than in dogs receiving the combination (299 days). Treatment was well tolerated in both arms. Conclusions: Piroxicam significantly enhanced the activity of vinblastine in dogs with UC where the cancer closely mimics the human condition, clearly justifying further study. The study suggest the potential importance of tracking COX inhibitor use in patients in clinical trials as COX inhibitors could affect treatment response.
Collapse
Affiliation(s)
- Deborah W Knapp
- Department of Veterinary Clinical Sciences, Purdue University, West Lafayette, IN, USA; Purdue University Center for Cancer Research, Purdue University, West Lafayette, IN, USA
| | | | - José A Ramos-Vara
- Department of Comparative Pathobiology, Purdue University , West Lafayette, IN, USA
| | | | | | - Sonia I Honkisz
- Department of Veterinary Clinical Sciences, Purdue University , West Lafayette, IN, USA
| |
Collapse
|